GO:0046676 negative regulation of insulin secretion: Signaling Pathways, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046676 (negative regulation of insulin secretion) describes any process that stops, prevents, or reduces the regulated release of insulin.
• It is a biological_process term in the Gene Ontology, with synonyms including down regulation of insulin secretion and inhibition of insulin secretion.
• Key negative regulators include extended synaptotagmin-1 (ESYT1), ATPase inhibitory factor 1 (ATP5IF1), β-cell-derived exosomes, and dopamine signaling [1,4,5,8].
• Dysregulation of this process contributes to type 2 diabetes, hyperinsulinism, and metabolic syndrome [2,7].
• Research tools include CRISPR knockout, point mutation, knock-in, overexpression models, and CRISPR library screening.
• Understanding negative regulation of insulin secretion is critical for developing therapies that restore β-cell function.
Description
Insulin secretion from pancreatic β cells is a tightly controlled process essential for glucose homeostasis. Negative regulation of insulin secretion (GO:0046676) encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of insulin release. This regulation is vital to prevent hyperinsulinemia and hypoglycemia, and its dysregulation is implicated in metabolic disorders such as type 2 diabetes. Researchers study this term to identify molecular brakes on insulin secretion, which could be targeted therapeutically. The Gene Ontology defines GO:0046676 as a biological process that negatively regulates the regulated release of insulin. Multiple mechanisms contribute, including feedback inhibition by extended synaptotagmin-1, dopaminergic signaling, and exosome-mediated communication. Understanding these pathways provides insights into β-cell physiology and disease.
negative regulation of insulin secretion At A Glance
| GO ID | GO:0046676 |
|---|---|
| GO term | negative regulation of insulin secretion |
| Ontology | biological_process |
| Synonym | down regulation of insulin secretion, down-regulation of insulin secretion, downregulation of insulin secretion, inhibition of insulin secretion |
| Major function | Reduces the frequency, rate, or extent of insulin release from pancreatic β cells |
| Related processes | Regulation of insulin secretion, glucose homeostasis, β-cell exocytosis |
| Key regulators | ESYT1, ATP5IF1, RGS4, dopamine receptors, exosomes |
| Disease relevance | Type 2 diabetes, hyperinsulinism, metabolic syndrome |
What Is GO:0046676?
GO:0046676, negative regulation of insulin secretion, is defined as any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of insulin. This biological process acts as a brake on insulin exocytosis, ensuring that insulin secretion is appropriately matched to metabolic demand and preventing excessive insulin release.
Why Is negative regulation of insulin secretion Important in Cell Biology?
Negative regulation of insulin secretion is crucial for maintaining glucose homeostasis and preventing hyperinsulinemia. Dysregulation of this process can lead to hypoglycemia, insulin resistance, and type 2 diabetes. Understanding the molecular players involved, such as extended synaptotagmin-1 and ATPase inhibitory factor 1, offers potential therapeutic targets. Moreover, β-cell-derived exosomes negatively regulate insulin secretion in recipient β cells, highlighting intercellular communication. This process is also modulated by nutrients, hormones, and neurotransmitters like dopamine. Therefore, studying GO:0046676 is essential for deciphering the complex control of insulin release and developing interventions for metabolic diseases.
• Prevents hyperinsulinemia and hypoglycemia by braking insulin release.
• Dysregulation contributes to type 2 diabetes pathogenesis.
• Involved in congenital hyperinsulinism through glutamate dehydrogenase mutations.
• Modulated by dopamine, offering neurological control of insulin secretion.
• Exosomes from β cells can negatively regulate insulin secretion in recipient cells.
• ATPase inhibitory factor 1 (IF1) regulates glucose-stimulated insulin secretion.
• mTOR signaling influences β-cell mass and insulin secretion.
• SPARC down-regulates RGS4 to promote insulin secretion, indicating negative regulation by RGS4.
• Feedback regulation by extended synaptotagmin-1 fine-tunes secretion.
• Targeting negative regulators may restore β-cell function in diabetes.
What Happens During negative regulation of insulin secretion?
Feedback inhibition by extended synaptotagmin-1
In simple terms: A protein called ESYT1 acts as a brake on insulin release after secretion starts.
Extended synaptotagmin-1 (ESYT1) is a calcium-dependent lipid-binding protein that localizes to the plasma membrane. It negatively regulates insulin secretion by feedback inhibition, possibly by modulating membrane lipid composition or exocytosis machinery. This ensures that insulin release is not excessive.
Dopaminergic inhibition
In simple terms: Dopamine, a brain chemical, can reduce insulin secretion from pancreatic islets.
Dopamine and dopamine receptor agonists inhibit insulin secretion from pancreatic β cells. This regulation involves D2-like receptors and downstream signaling that reduces cAMP levels and calcium influx, thereby decreasing exocytosis. This provides a neuroendocrine brake on insulin release.
Exosome-mediated negative regulation
In simple terms: Small vesicles released by β cells can tell other β cells to secrete less insulin.
β-cell-derived exosomes can negatively regulate glucose-stimulated insulin secretion in recipient β cells. These exosomes carry specific cargo that modulates signaling pathways in target cells, reducing insulin release. This represents a form of intercellular communication that dampens secretion.
ATPase inhibitory factor 1 (IF1) modulation
In simple terms: IF1, a mitochondrial protein, can adjust insulin secretion based on cellular energy status.
ATPase inhibitory factor 1 (IF1) regulates glucose-stimulated insulin secretion. Overexpression of IF1 reduces insulin secretion, likely by affecting mitochondrial ATP production and downstream signaling. This links mitochondrial function to negative regulation of insulin secretion.
Regulation by RGS4 and SPARC
In simple terms: RGS4 protein dampens insulin secretion, while SPARC reduces RGS4 to enhance secretion.
Regulator of G protein signaling 4 (RGS4) negatively regulates insulin secretion by accelerating the inactivation of G protein subunits. SPARC (secreted protein acidic and rich in cysteine) promotes insulin secretion through down-regulation of RGS4 protein in pancreatic β cells. Thus, RGS4 acts as a negative regulator, and its suppression enhances secretion.
Key Genes Involved in GO:0046676 negative regulation of insulin secretion
The following genes and proteins are key players in the negative regulation of insulin secretion, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ESYT1 | Feedback inhibition of insulin secretion | Calcium-dependent lipid-binding protein; KO enhances secretion |
| ATP5IF1 | Mitochondrial ATPase inhibitor; reduces insulin secretion | Overexpression decreases glucose-stimulated insulin secretion |
| RGS4 | Negative regulator of insulin secretion | Down-regulated by SPARC to promote secretion |
| SPARC | Promotes insulin secretion by down-regulating RGS4 | Overexpression enhances secretion |
| DRD2 | Dopamine receptor D2; inhibits insulin secretion | Agonists reduce secretion |
| DRD3 | Dopamine receptor D3; inhibits insulin secretion | Part of dopaminergic regulation |
| DRD4 | Dopamine receptor D4; inhibits insulin secretion | Part of dopaminergic regulation |
| GLUD1 | Glutamate dehydrogenase; regulates insulin secretion | Mutations cause hyperinsulinism |
| MTOR | mTOR kinase; modulates β-cell mass and secretion | Inhibition affects insulin secretion |
| Exosomes | β-cell-derived vesicles that negatively regulate secretion | Intercellular communication |
| SLC2A2 | Glucose transporter GLUT2; affects secretion | Nutrient regulation |
| GCK | Glucokinase; glucose sensing | Nutrient regulation |
| KCNJ11 | Potassium channel Kir6.2; regulates secretion | Nutrient regulation |
| ABCC8 | Sulfonylurea receptor 1; regulates secretion | Nutrient regulation |
| CACNA1C | Calcium channel; mediates exocytosis | Nutrient regulation |
| SNAP25 | SNARE protein; exocytosis machinery | Nutrient regulation |
| STX1A | Syntaxin 1A; exocytosis machinery | Nutrient regulation |
How Is negative regulation of insulin secretion Regulated?
Negative regulation of insulin secretion is modulated by various signaling pathways. mTOR signaling influences β-cell mass and insulin secretion, with mTOR inhibition affecting secretion. Nutrient status, including glucose and amino acids, regulates insulin secretion and its negative feedback. Dopaminergic signaling via D2-like receptors provides inhibitory control. Additionally, exosomes from β cells can negatively regulate secretion in recipient cells. These regulatory layers ensure tight control of insulin release.
negative regulation of insulin secretion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GLUD1 | Congenital hyperinsulinism | Knock-in mouse with GLUD1 mutation |
| RGS4 | Type 2 diabetes | β-cell-specific RGS4 knockout |
| SPARC | Type 2 diabetes | SPARC overexpression in β cells |
| DRD2 | Metabolic syndrome | DRD2 knockout mouse |
| ESYT1 | Insulin secretion dysregulation | ESYT1 knockout β cells |
Type 2 Diabetes
In type 2 diabetes, impaired negative regulation of insulin secretion can contribute to hyperinsulinemia and β-cell exhaustion. Dysregulation of pathways involving RGS4, SPARC, and exosomes may exacerbate disease progression [3,8]. Understanding these mechanisms could lead to new therapeutic strategies.
Congenital Hyperinsulinism
Mutations in GLUD1, which encodes glutamate dehydrogenase, cause hyperinsulinism by increasing insulin secretion. This highlights the importance of negative regulation; loss of inhibitory control leads to excessive insulin release.
Metabolic Syndrome
Dopaminergic regulation of insulin secretion is altered in metabolic syndrome, contributing to dysregulated insulin release. Targeting dopamine receptors may restore negative regulation.
From negative regulation of insulin secretion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ESYT1 negatively regulate insulin secretion? | ESYT1 knockout β-cell line |
| Does IF1 overexpression reduce insulin secretion? | IF1 overexpression in INS-1 cells |
| Does RGS4 down-regulation enhance secretion? | RGS4 point mutation (GTPase-activating deficient) |
| Does SPARC promote secretion via RGS4? | SPARC knock-in with tagged RGS4 |
| Does exosome cargo inhibit secretion? | Exosome isolation and treatment of recipient β cells |
| Does dopamine inhibit secretion via D2 receptors? | DRD2 knockout mouse islets |
How to Study the negative regulation of insulin secretion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Gene function in insulin secretion | Identify negative regulators |
| Live-cell imaging | Real-time insulin exocytosis | Assess ESYT1 feedback |
| Proteomics | Protein composition of exosomes | Exosome cargo analysis |
| Seahorse assay | Mitochondrial respiration | IF1 effects on secretion |
| ELISA | Insulin concentration | Quantify secretion |
| Patch-clamp | Ion channel activity | Dopamine receptor effects |
| RNA-seq | Transcriptional changes | Identify pathways |
| CRISPR library screening | High-throughput gene function | Discover novel regulators |
CRISPR Knockout Screens
Genome-wide CRISPR knockout screens can identify genes whose loss enhances or suppresses insulin secretion. This approach has revealed negative regulators like ESYT1 and RGS4.
Live-Cell Imaging
Live-cell imaging with fluorescent insulin reporters allows real-time monitoring of secretion dynamics. This can assess the impact of negative regulators on exocytosis.
Proteomics and Interactomics
Proteomic analysis of β-cell exosomes and interactomes can uncover cargo and signaling molecules involved in negative regulation.
Metabolic Assays
Seahorse assays and ATP measurements can evaluate mitochondrial function and its role in negative regulation, such as IF1 effects.
How CRISPR Can Be Used to Study GO:0046676 negative regulation of insulin secretion
Knockout
CRISPR knockout of negative regulators like ESYT1 or RGS4 can enhance insulin secretion, validating their roles [1,3]. Knockout models are essential for causal inference.
Point Mutation
Introducing point mutations in genes such as GLUD1 can mimic disease-associated variants and assess their impact on negative regulation.
Knock-in
Knock-in of tagged proteins (e.g., GFP-RGS4) allows tracking of localization and dynamics in β cells.
Overexpression
Overexpression of IF1 or SPARC can test their sufficiency in negatively regulating insulin secretion [3,5].
How EDITGENE Supports negative regulation of insulin secretion Research
Researchers studying negative regulation of insulin secretion-related genes often need to determine whether a candidate gene is causally involved in modulating insulin release. EDITGENE provides comprehensive CRISPR services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of insulin secretion research.
Frequently Asked Questions About negative regulation of insulin secretion
What is negative regulation of insulin secretion?
It is any process that stops, prevents, or reduces the frequency, rate, or extent of insulin release, defined as GO:0046676.
What genes are involved in negative regulation of insulin secretion?
Key genes include ESYT1, ATP5IF1, RGS4, DRD2, and GLUD1 [1,3,4,5,7].
How does ESYT1 negatively regulate insulin secretion?
ESYT1 provides feedback inhibition of insulin secretion, likely by modulating membrane dynamics.
What is the role of dopamine in insulin secretion?
Dopamine inhibits insulin secretion via D2-like receptors on β cells.
How do exosomes negatively regulate insulin secretion?
β-cell-derived exosomes can transfer cargo to recipient β cells and reduce glucose-stimulated insulin secretion.
What diseases are associated with dysregulated negative regulation of insulin secretion?
Type 2 diabetes, congenital hyperinsulinism, and metabolic syndrome [2,7].
How can CRISPR be used to study negative regulation of insulin secretion?
CRISPR knockout, point mutation, knock-in, and overexpression models can validate gene function [1,3,5].
What is the role of IF1 in insulin secretion?
IF1 overexpression reduces glucose-stimulated insulin secretion, linking mitochondrial function to negative regulation.
How does RGS4 affect insulin secretion?
RGS4 negatively regulates insulin secretion; its down-regulation by SPARC enhances secretion.
What methods are used to study negative regulation of insulin secretion?
CRISPR screens, live-cell imaging, proteomics, and metabolic assays [1,5,8].
Conclusion
Negative regulation of insulin secretion (GO:0046676) is a critical biological process that prevents excessive insulin release. Key regulators such as ESYT1, IF1, RGS4, and dopamine signaling provide multiple layers of control [1,3,4,5]. Dysregulation of this process contributes to metabolic diseases, making it a promising therapeutic target. Advances in CRISPR technology enable precise interrogation of these pathways, and EDITGENE offers comprehensive services to support such research.
References
- 1. Xie B et al.. 2019. Feedback regulation of insulin secretion by extended synaptotagmin-1.. FASEB J 33(4):4716-4728 PMID: 30589572
- 2. Newsholme P et al.. 2014. Nutrient regulation of insulin secretion and action.. J Endocrinol 221(3):R105-20 PMID: 24667247
- 3. Hu L et al.. 2020. SPARC promotes insulin secretion through down-regulation of RGS4 protein in pancreatic β cells.. Sci Rep 10(1):17581 PMID: 33067534
- 4. Ustione A et al.. 2013. Minireview: Dopaminergic regulation of insulin secretion from the pancreatic islet.. Mol Endocrinol 27(8):1198-207 PMID: 23744894
- 5. Kahancová A et al.. 2018. Regulation of glucose-stimulated insulin secretion by ATPase Inhibitory Factor 1 (IF1).. FEBS Lett 592(6):999-1009 PMID: 29380352
- 6. Asahara SI et al.. 2022. Roles of mTOR in the Regulation of Pancreatic β-Cell Mass and Insulin Secretion.. Biomolecules 12(5) PMID: 35625542
- 7. Stanley CA. 2009. Regulation of glutamate metabolism and insulin secretion by glutamate dehydrogenase in hypoglycemic children.. Am J Clin Nutr 90(3):862S-866S PMID: 19625687
- 8. Yu CC et al.. 2024. A negative regulatory role of β-cell-derived exosomes in the glucose-stimulated insulin secretion of recipient β-cells.. Arch Toxicol 98(11):3885-3896 PMID: 39127846
